



Memorial Sloan-Kettering
Cancer Center

Update

IN GYNECOLOGIC ONCOLOGY

SELECTED CLINICAL TREATMENT PROTOCOLS (REVISED AUGUST 19, 2011)

OVARIAN CANCER

Dennis Chi (01-048)

The Utility and Impact of Computed Tomography and Serum CA-125 in the Management of Newly Diagnosed Ovarian Cancer
212-639-5016

Roisin O'Cearbhaill (06-155)

A Phase I Dose Escalation Safety and Feasibility Study of WT1-Specific T Cells for the Treatment of Patients with Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Carcinomas
212-639-4820

Mario Leitao (08-074)

A Phase III, Randomized, Controlled, Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary, and Fallopian Tube Cancer
212-639-3987

Katherine Bell-McGuinn (08-097/GOG 0235)

A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy
212-639-8396

Noah Kauff (08-150/GOG 214)

Phase II, Double-Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
646-888-4082

Mario Leitao (09-167/GOG-0252)

A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: NCI Supplied Agent: Bevacizumab
212-639-3987

Mario Leitao (11-007/GOG 263)

A Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Patients with Intermediate-Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
212-639-3987

Mario Leitao (11-008/GOG-262)

A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin With or Without Concurrent and Consolidation Bevacizumab in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
212-639-3987

Katherine Bell-McGuinn (09-154)

A Phase I Study of ABT-888 in Combination with Carboplatin and Gemcitabine in Subjects with Advanced Solid Tumors
212-639-8396

Roisin O'Cearbhaill (10-184)

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in the Treatment of Patients with Recurrent, Platinum-sensitive, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
212-639-4820

Katherine Bell-McGinn (09-106/GOG 9923)

A Phase I Study of Carboplatin/Paclitaxel/CTEP Supplied Agent Bevacizumab and CTEP Supplied Agent ABT-888 in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
212-639-8396

Jason Konner (08-149)

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer
212-639-8151

Paul Sabbatini (09-018/GOG-0255)

A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate + OPT-821 Versus OPT-821 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
212-639-6423

Paul Sabbatini (09-184)

Phase I Trial of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
212-639-6423

Paul Sabbatini (10-099)

A Pilot Study of a Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination with Bevacizumab in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Second or Greater Complete or Partial Clinical Remission
212-639-6423

William Tew (10-168/GOG-0186G)

A Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
212-639-6555

CERVICAL CANCER

Mario Leitao (09-098/GOG 0240)

A Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and without NCI-Supplied Bevacizumab Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, with and without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
212-639-3987

Mario Leitao (10-173/GOG 0724)

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
212-639-3987

ENDOMETRIAL CANCER

Carol Aghajanian (09-115/GOG-0086-P)

A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus and Ixabepilone/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
212-639-2252

Carol Aghajanian (09-174/GOG-0249)

A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early-Stage Endometrial Carcinoma
212-639-2252

Mario Leitao (09-145/GOG-0258)

A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
212-639-3987

UTERINE CANCER

Martee Hensley (11-064/GOG-0230D)

A Phase I Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
212-639-6902

Martee Hensley (10-007/GOG-261)

A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus
212-639-6902

Martee Hensley (10-048/GOG 250)

A Randomized Phase III Evaluation of Docetaxel and Gemcitabine Plus G-CSF with Bevacizumab Versus Docetaxel and Gemcitabine Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus, NCI Supplied Agent: Bevacizumab
212-639-6902

PSYCHOLOGY / QUALITY OF LIFE

Dennis Chi (05-001)

A Prospective Study of Quality of Life in Patients Undergoing Total Pelvic Exenteration
212-639-5016

Dennis Chi (08-155)

Electronic Patient-Reported Outcomes from Home in Patients Recovering from Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-Related Quality of Life
212-639-5016

Jeanne Carter (10-034)

A Pilot Study Surveying Female Cancer Patients' Preference for Sexual Health Interventions
646-888-5076

Ginger J. Gardner (10-030)

Psychological Interventions for Gynecological Cancer
212-639-2375

CLINICAL TRIALS – NONSPECIFIC DISEASE SITES

Dennis Chi (07-029)

A Pilot Study of Topical Imiquimod Therapy for the Treatment of Recurrent Extramammary Paget's Disease
212-639-5016

Katherine Bell-McGuinn (09-101)

A Phase I Study of PKI-587 Administered as an Intravenous Infusion to Subjects with Solid Tumors
212-639-8396